HEALTHCARE RESEARCH GOVERNANCE OVERVIEW

1 INTRODUCTION

The MND Association’s vision is a world free from MND.

A published Research Strategy highlights the activities through which our research funding programmes seek to deliver significant and measurable advances in understanding and treating the disease. To ensure the quality and relevance of the research funded by the MND Association, applications for funding of research projects are evaluated by peer review.

Peer review is carried out by the Healthcare Research Advisory Panel (HRAP) comprising healthcare researchers, clinicians and patient/carer representatives. HRAP members are appointed by the Board of Trustees on the recommendation of the director of research development. The director of research development may consult the HRAP and the wider MND healthcare community on suitable candidates.

The purpose of this document is to inform applicants and members of the HRAP about relevant MND Association policies and procedures in relation to research funding.

2 GENERAL CONSIDERATIONS

The Panel has no responsibility for decisions concerning the size of the research budget. This is fixed annually by the Board of Trustees, which has ultimate responsibility for the allocation of funds.

2.1 HRAP is responsible for the assessment and rating of applications for research funding. HRAP makes a recommendation to the Board of Trustees of the MND Association, based upon its considerations. The Board of Trustees is responsible for setting annual budgets and the formal offer of new research grants.

2.2 Research Practice

The research institute where the grant is awarded is responsible for the research practice of each research grant. It is responsible for ensuring that the necessary legal and regulatory requirements are met by the grant holder and approvals obtained before the commencement of the research grant and during the full research grant period. The research institute must have in place formal procedures for the handling of allegations of misconduct.
2.3 **Confidentiality**

By agreeing to become a member of the HRAP, an individual undertakes not to use or disclose any information obtained in the course of their membership for any purpose other than considering the relevant research or application under review, without the written consent of the Association. The Association will seek the consent of any concerned party prior to providing such written consent. This clause does not apply to any information already in the public domain prior to its disclosure via the HRAP. No copies shall be made of any information obtained via the HRAP and any documents (including electronic copies) obtained via the panel, shall be destroyed/deleted or returned to the Association upon request. The supply of any information to panel members by the Association does not create any licence, title or interest in respect of any intellectual property rights. Panel members must not discuss with applicants or reviewers any information relating to the review of a specific application or offer opinions on the chances of success or failure. All requests for information about an application or a reviewer report should be referred to the Association’s Research Grants Team.

Applications involving industrial partners may contain confidential and commercially sensitive information. In order to make such information available to members of the HRAP, to assist in the evaluation process of applications, the director of research development may sign a Confidentiality Agreement on behalf of the MND Association. Panel members must hold such information in strict confidence and not make use of the information other than for the purposes of evaluating a funding application.

Applicants have the right to request access to all information held about themselves and their application. Therefore, written material used to evaluate an application may be made available to the applicants. The identity of the reviewers will not be revealed to the applicants.

2.4 **Conflict of Interest**

The Association will make every effort to ensure that its decisions are fair and objective and are also seen to be so. HRAP members must declare any potential conflict of interest. If a conflict of interest is deemed to exist, then the panel member will not participate in the review of an application.

**Guidelines for disclosing conflicts of interest** include panel members who:

- Are from the same immediate institution (same department/unit) as the applicant, and who interact with the applicant in the course of their duties at the institution.
- Have collaborated, published or been a co-applicant with the applicant, within the last five years.
- Have been a student or supervisor of the applicant within the last five years.
- Are a close personal friend or relative of the applicant.
- Have had long-standing scientific or personal differences with the applicant.
- Are in a position to gain or lose financially from the outcome of the application (eg hold stock in a company of an industry partner or a competitor).
- For any other reason feel that they cannot provide an objective review of the application.
All panel members must declare a conflict of interest in advance of reviewing an application. The director of research development is responsible for resolving areas of uncertainty.

The staff of the Association are subject to the same conflict of interest guidelines as regular panel members.

All panel members must agree to abide by the above confidentiality clause (paragraph 2.3) and the guidelines for declaring conflicts of interest (paragraph 2.4) when they join the panel. Members are asked to sign a form of agreement on appointment to the panel.

3 ROLE OF PANEL MEMBERS

3.1 HRAP Members
Unless they have a conflict of interest, all panel members will review each application received for consideration and will be asked to provide confidential, constructive comments, when possible, to feedback to applicants.

3.2 Trustee Members of HRAP
MND Association trustee members of HRAP are trustees of the Association who have a demonstrated interest in healthcare research and/or practice. The trustees help to ensure that Association funding is in accordance with its strategic objectives. They also ensure the panel considers the relevance of the proposed research to people affected by MND and the likelihood of tangible benefits arising from the funding.

The duties of a trustee member include:

- Ensuring that the proposed research has a clear focus on people affected by MND, with clearly stated outcomes for improving treatment and/or clinical management.
- Providing feedback on the general working of the panel such as the quality of work reviewed by the panel, the structure of the discussions, the objective nature of the discussions and any other general comments.
- Providing assurance to the full Board of Trustees that all funding discussions and recommendations were conducted according to ‘due process’.

4 REPORTS ON GRANT PROGRESS

4.1 Grantees must submit to the Association:

4.1.1 Annual progress reports: required within four weeks of the anniversary of the start date, using the Association’s annual report form. A detailed report covering the whole year is required for review by members of HRAP. A short summary in language intelligible to the lay reader should also be submitted for possible use in Association publications.

4.1.2 Interim reports: if the project is funded through the Association’s major donor scheme, the grantee may be required to provide brief 6-monthly reports of no more than two pages. These reports are subject to review by the director of research development, not by the HRAP.
4.1.3 **Final report**: required within **six weeks** of the end of the project using the Association’s final report form. A detailed final report covering the whole project is required for review by members of HRAP. A summary should also be provided in language intelligible to the lay reader. Grantees must avoid the use of jargon and technical language and should pitch the summary at the level of a science feature in a broadsheet newspaper.

This may be used in Association publications.

4.1.4 The final instalment of the grant will be paid after receipt of the final report and its approval, by members of the HRAP. Payment may be delayed further if reports are not submitted on time and/or if clarification is required.

5 **HRAP PROCESS FOR REVIEW OF REPORTS**

5.1 Panel members who are reviewing annual/final reports should be familiar with the main objectives of the project and the applicant’s experience.

5.2 A copy of the annual or final report will be forwarded to two panel members (along with the original application and past reports if required). They should review the work carried out to date, the likelihood of the project achieving its goals and highlight any problems of which the Association should be aware.

Panel members are asked to provide feedback via email. These comments will be passed on anonymously to the applicant, who has the chance to respond, if required.